Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs --
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) infections.
"We are excited to have Dr. Gaggar join Assembly Bio's leadership team at an incredibly important time for the organization," said Jason Okazaki, chief executive officer and president. "Anuj's depth and breadth of experience in successfully developing life-changing antiviral therapies will be instrumental to executing on our plans to have four portfolio compounds in the clinic in 2024, with the goal of improving the lives of patients suffering from herpesviruses and viral hepatitis."
"I am thrilled to join Assembly Bio in its commitment to bringing next-generation antiviral treatments to patients," said Dr. Gaggar. "The programs targeted to be in the clinic next year—two long-acting helicase-primase inhibitors for herpes simplex virus, next-generation capsid assembly modulator ABI-4334 for the treatment of HBV, and orally bioavailable HDV entry inhibitor ABI-6250—offer the potential to improve therapeutic options for patients in areas with significant unmet medical need. I look forward to working with the strong scientific organization at Assembly Bio to advance these programs."
Dr. Gaggar joins ...
Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.